Akebia Therapeutics (NASDAQ: AKBA) and Progenics Pharmaceuticals (NASDAQ:PGNX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.
Valuation and Earnings
This table compares Akebia Therapeutics and Progenics Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Akebia Therapeutics||$177.98 million||2.99||-$76.91 million||($1.77)||-5.36|
|Progenics Pharmaceuticals||$11.70 million||45.21||-$51.01 million||($0.90)||-8.09|
This table compares Akebia Therapeutics and Progenics Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk and Volatility
Akebia Therapeutics has a beta of 1.09, meaning that its share price is 9% more volatile than the S&P 500. Comparatively, Progenics Pharmaceuticals has a beta of 2.46, meaning that its share price is 146% more volatile than the S&P 500.
This is a summary of current ratings for Akebia Therapeutics and Progenics Pharmaceuticals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Akebia Therapeutics presently has a consensus target price of $23.50, suggesting a potential upside of 147.89%. Progenics Pharmaceuticals has a consensus target price of $13.75, suggesting a potential upside of 88.87%. Given Akebia Therapeutics’ higher possible upside, equities analysts plainly believe Akebia Therapeutics is more favorable than Progenics Pharmaceuticals.
Insider & Institutional Ownership
69.6% of Akebia Therapeutics shares are owned by institutional investors. Comparatively, 83.7% of Progenics Pharmaceuticals shares are owned by institutional investors. 8.0% of Akebia Therapeutics shares are owned by insiders. Comparatively, 3.6% of Progenics Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Progenics Pharmaceuticals beats Akebia Therapeutics on 8 of the 15 factors compared between the two stocks.
Akebia Therapeutics Company Profile
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for patients with renal disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease in dialysis and non-dialysis patients. The company is also developing a HIF-based portfolio of product candidates, such as AKB-5169, a preclinical compound for the treatment of inflammatory bowel disease. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of HIF-prolyl hydroxylases-targeted compounds internationally. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Progenics Pharmaceuticals Company Profile
Progenics Pharmaceuticals, Inc. is engaged in developing medicines and other products for targeting and treating cancer. The Company’s pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools. It also includes commercial product, RELISTOR (methylnaltrexone bromide) for opioid-induced constipation. AZEDRA is a radiotherapeutic product candidate in development as a treatment for malignant and/or recurrent pheochromocytoma and paraganglioma, rare tumors found in the adrenal glands and outside of the adrenal glands, respectively. RELISTOR is a treatment for opioid induced constipation. PyL is a clinical-stage, fluorinated PSMA-targeted Positron Emission Topography (PET) imaging agent for prostate cancer. PSMA TTC is a thorium-227 labeled PSMA-targeted antibody therapeutic.
Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.